Lobbying

GSK's latest lobbying report covers Q2 2026, at $890K. The four quarters Q3 2025–Q2 2026 total $5M. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Copyright/Patent/Trademark.

GSK

Latest quarter
$890K
Q2 2026 · 1 reports
Last 12 months
$5M
Last 4 quarters
vs last quarter
−45.7%
Q2 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

GSK lobbying by quarter
GSK lobbying by quarter
QuarterAmountReports
Q4 2022$860K1
Q1 2023$1.7M1
Q2 2023$900K1
Q3 2023$1M1
Q4 2023$1.5M1
Q1 2024$820K1
Q2 2024$1.5M1
Q3 2024$1.5M1
Q4 2024$920K1
Q1 2025$800K1
Q2 2025$1.5M1
Q3 2025$1.7M1
Q4 2025$810K1
Q1 2026$1.6M1
Q2 2026$890K1

Policy issues the reports name

  • Budget and appropriations15 reports
  • Copyright, patent and trademark15 reports
  • Health issues15 reports
  • Medicare and Medicaid15 reports
  • Trade15 reports

A report that names several issues counts once for each.

Who was lobbied

  • Centers For Medicare and Medicaid Services (CMS)15 reports
  • Health & Human Services, Dept of (HHS)15 reports
  • HOUSE OF REPRESENTATIVES15 reports
  • Office of Management & Budget (OMB)15 reports
  • Patent & Trademark Office (PTO)15 reports
  • SENATE15 reports
  • U.S. Trade Representative (USTR)15 reports

Firms it paid

Firm
In-houseGSK$18.1M15 quarters

Former officials lobbying for it

Former position
CARA WALTHERCong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017Q2 2026
JASEY CARDENASCong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016Q2 2026
HARMEET DHILLONNational Science Foundation: Intern (May 2007-Dec 2007)Q3 2024
LIAM MACDONALDSen. Mike Rounds (R-SD)Legislative Assistant; April 11, 2022-April 11, 2024 Rep.Tim Burchett (R-TN-02)Legislative Assistant; November 2020-April 2022 Rep. Phil Roe (R-TN-01)Legislative Assistant; March 2020-November 2020Q2 2024

Lobbying reports

Filed by
07/16for Q2In-house$890K
04/20for Q1In-house$1.6M
01/20for Q4 2025In-house$810K
25/10/20for Q3 2025In-house$1.7M
25/07/21for Q2 2025In-house$1.5M
25/05/06for Q1 2025In-house$800K
25/04/21for Q1 2025In-house$800K
25/01/21for Q4 2024In-house$920K
24/10/21for Q3 2024In-house$1.5M
24/07/22for Q2 2024In-house$1.5M
24/04/22for Q1 2024In-house$820K
24/01/22for Q4 2023In-house$1.5M
23/10/20for Q3 2023In-house$1M
23/07/20for Q2 2023In-house$900K
23/04/20for Q1 2023In-house$1.7M
23/01/20for Q4 2022In-house$860K